1			Appendix			
∠ 3	Methods					
4	Site and sample c	ollection. Two w	vastewater treatment plants (WWTPs) servi	na Montaomerv		
5	County, Texas were	e selected for the	e study. The WWTP186 and WWTP187 ser	ve 65,000 and		
6	70,000 people, respectively (Figure 1). The locations were chosen because Montgomery					
7	County recorded a	large number of	parvovirus infections during the study perio	d based on data		
8	from Epic Cosmos	(see below). Fifty	milliliters of 24-hour composite raw waster	water influent		
9	samples were colle	cted using sterile	e containers by WWTP staff approximately t	hree times per		
10	week between 18 D	ecember 2023 a	and 30 August 2024. Samples were sent at	4°C to the		
11	laboratory where th	ey were process	ed immediately. Time between sample colle	ection and		
12	receipt at the lab wa	as typically betwe	een 1-3 days, during this time, we expect lir	nited		
13	degradation of the I	RNA targets ¹ . A t	total of 220 unique samples were processed	d. At the lab, the		
14	wastewater solids were collected from the influent by settling for 10–15 min, and using a					
15	serological pipette t	o aspirate the se	ettled solids into another tube.			
16						
1/ 10	Assay specificity a	and sensitivity 1 P_{10}^{2} (here	testing. We used a previously developed h	ydrolysis-probe		
10	etructural protoin 1		earter referred to as BISV) that targets the	d the accovin		
20	structural protein 1 (NOT). TO ensure assay specificity and sensitivity, we tested the assay in silico, and in vitro against virus as bacteria, and synthetic generates (Table 1). Nucleic aside					
20	since, and in vitre against viruses, bacteria, and synthetic generies (Table T). NUCleic-acids					
22	wastewater solids samples and then used neat as template in dronlet digital the 1-step RT-PCR					
23	assay. The assay was run in a single well using the cycling conditions and post processing					
24	using a droplet reader as described below for the wastewater samples in singleplex. Synthetic					
25	parvovirus B19 genomic DNA (ATCC VR-3281SD) was used as a positive control.					
26		·	<i>,</i>			
27	For in silico analysis	s, the primers an	d probes were first compared to the referer	ice genome		
28	(NC_000883.2) from	n National Cente	er for Biotechnology Information (NCBI) to e	nsure 100%		
29	alignment. After this	s, genomes from	1 January 2024 to 1 October 2024 were do	ownloaded from		
30	NCBI Virus (n=277) and a consensus genome was generated. The assay was then checked					
31	against this consensus genome, as well as a subset of individual genomes from the above list.					
32	After this, the prime	ers and probes w	ere run through NCBI Blast, excluding Erytl	hroparvovirus		
33	primate1 (synonym	ous with parvovi	rus B19) and parvovirus B19, to identify pot	ential off-target		
34	hits.					
35	Table S1. Viruses us	sed to test specif	icity are indicated as "non target testing" an	d viruses used		
36	positive controls are	e indicated as "ta	rget testing". All non-target controls are sol	d by Zeptomatrix		
37	(Buffalo, NY), ATCC	(American Type	Culture Collection, location), and TWIST (So	uth San		
38	Francisco, CA). All t	the viruses from A	∠eptometrix are included in the NATtrol™ Re ເຄຍເວ	spiratory		
29	vernication Panel (C	Jalaloy #: NATRS	рг-ы <i>0</i> ј.			
	Virus	Genomic	Non-target testing	Target testing		

virus	target	non-target testing (negatives)	(positives)
Parvovirus B19	Non-structural	Parainfluenza 1 (NATRSP-BIO, Zeptometrix)	Parvovirus B19

<i>B. parapertussis</i> (Zeptometrix) <i>B. pertussis</i> (Zeptometrix) Synthetic Influenza B RNA (Twist #103003) Synthetic Influenza A H1N1 RNA (Twist #103001) Synthetic Influenza A H3N2 RNA (Twist #103002) Genomic SARS-CoV-2 gRNA (ATCC VR-	(B19V)	protein 1 (NS1)	Parainfluenza 2 (Zeptometrix) Parainfluenza 3 (Zeptometrix) Parainfluenza 4 (Zeptometrix) Influenza A H1N1pdm (Zeptometrix) Influenza AH1 (Zeptometrix) Influenza AH3 (Zeptometrix) Influenza B (Zeptometrix) Adenovirus 1 (Zeptometrix) Adenovirus 3 (Zeptometrix) Adenovirus 31 (Zeptometrix) RSV A (Zeptometrix) RSV A (Zeptometrix) RSV A (Zeptometrix) RSV B (Zeptometrix) SARS-CoV-2 (Zeptometrix) <i>M. pneumoniae</i> (Zeptometrix) <i>M. pneumoniae</i> (Zeptometrix) <i>M. pneumoniae</i> (Zeptometrix) Coronavirus HKU-1 (Zeptometrix) Coronavirus OC43 (Zeptometrix) <i>Coronavirus</i> OC43 (Zeptometrix) <i>B. parapertussis</i> (Zeptometrix) <i>B. parapertussis</i> (Zeptometrix) <i>Synthetic</i> Influenza B RNA (Twist #103003) Synthetic Influenza A H3N2 RNA (Twist #103002) Genomic SARS-CoV-2 (RE	DNA (ATCC VR- 3281SD)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------	-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------

40

Solids pre-analytical methods. Samples were further dewatered by centrifugation, and dewatered solids were suspended in DNA/RNA Shield (Zymo Research, Irvine, CA) at a concentration of 0.75 mg (wet weight)/ml. The DNA/RNA shield was spiked with bovine coronavirus (BCoV) vaccine as a RNA recovery control. This concentration of solids in buffer has been shown to alleviate inhibition in downstream RT-PCR ³. A separate aliquot of

46 dewatered solids was dried in an oven to determine dry weight. RNA was extracted from 6

47 replicate aliquots of dewatered settled solids suspended in the DNA/RNA Shield, and then it
48 was subsequently processed through an inhibitor removal kit. The pre-analytical methods are

- 49 also provided on protocols.io³.
- 50

51 RNA extraction and purification. RNA extraction and purification was done using the
52 Chemagic Viral DNA/RNA 300 kit H96 for the Perkin Elmer Chemagic 360 (Perkin Elmer,
53 Waltham, MA). It was followed by PCR inhibitor removal with the Zymo OneStep-96 PCR
54 Inhibitor Removal kit (Zymo Research, Irvine, CA). 300 µl of the suspension entered into the
55 nucleic-acid extraction process and 50 µl of nucleic-acids are retrieved after the inhibitor

- 56 removal kit.
- 57

58 **Digital droplet RT-PCR analytical methods.** Each replicate RNA extract from each sample (6 59 per sample) was processed to measure human viral nucleic-acid concentrations using digital 60 RT-PCR, each in its own well (6 replicate wells per sample). We quantified the number of copies 61 of B19V DNA using the previously established assay (Table 2). The assay was run in duplex

- 61 of B19V DNA using the previously established assay (Table 2). The assay was run in duplex 62 using the probe-mixing approach along with an assay for the SARS-CoV-2 N gene: the probe
- 63 used to detect B19V was labeled using FAM (6-fluorescein amidite), and the probe used for
- 64 SARS-CoV-2 was labeled with HEX (hexachlorofluorescein). Extraction negative (BCoV spiked
- 65 buffer, 2 wells) and positive (buffer spiked with positive control cDNA of SARS-CoV-2 target, 1
- 66 well) controls, and PCR negative (molecular grade water, 2 wells) and positive controls (cDNA,
- 1 well) were run on each 96 well plate. Nucleic-acids were stored between 2 and 10 months at -
- 68 80°C prior to these measurements.
- 69
- 70 ddRT-PCR was performed on 20 μl samples from a 22 μl reaction volume, prepared using 5.5 μl
- template, mixed with 5.5 µl of One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad
- 72 1863021), 2.2 μ l of 200 U/ μ l Reverse Transcriptase, 1.1 μ l of 300 mM dithiothreitol (DTT) and
- 73 primers and probes mixtures at a final concentration of 900 nM and 250 nM respectively. Primer
- and probes for assays were purchased from Integrated DNA Technologies (IDT, San Diego,
- 75 CA) (Table 2. B19V and SARS-CoV-2 nucleic-acids were measured in reactions with undiluted
- 76 template.77
- 78 Droplets were generated using the AutoDG Automated Droplet Generator (Bio-Rad, Hercules,
- 79 CA). PCR was performed using Mastercycler Pro (Eppendforf, Enfield, CT) with the following
- 80 cycling conditions: reverse transcription at 50 °C for 60 min, enzyme activation at 95 °C for
- 81 5 min, 40 cycles of denaturation at 95 °C for 30 s and annealing and extension at 59 °C for 30 s,
- 82 enzyme deactivation at 98 °C for 10 min then an indefinite hold at 4 °C. The ramp rate for
- 83 temperature changes were set to 2 °C/second and the final hold at 4 °C was performed for a
- 84 minimum of 30 min to allow the droplets to stabilize. Droplets were analyzed using the QX200
- 85 (Bio-Rad). A well had to have over 10,000 droplets for inclusion in the analysis. All liquid
- transfers were performed using the Agilent Bravo (Agilent Technologies, Santa Clara, CA).
- 87
- 88 Thresholding was done using QuantaSoft Analysis Pro Software (Bio-Rad, version 1.0.596). In
- 89 order for a sample to be recorded as positive, it had to have at least 3 positive droplets.
- 90 Replicate wells were merged for analysis of each sample.
- 91
- 92 These nucleic-acids were also processed immediately without any storage to measure
- concentrations of pepper mild mottle virus (PMMoV) RNA, BCoV RNA, and SARS-CoV-2 N
- gene RNA. PMMoV is highly abundant in wastewater globally⁴ and is used as an internal $\int_{-\infty}^{-\infty}$
- ⁹⁵ recovery and fecal strength control⁵. BCoV RNA is used as an exogenous viral nucleic acid
- 96 recovery control. The measurement of SARS-CoV-2 N gene RNA on fresh, unstored samples
- 97 can be compared to that measured in the stored samples (described above) as an indication of
- 98 nucleic-acid degradation during storage and freeze thaw. Details of these measurements, and
- 99 the measurements themselves, are published in Boehm et al.⁶
- 100

- 101
- 102

103 Table S2. Primer and hydrolysis probes targeting parvovirus B19² (B19V) and SARS-CoV-2 N

104 gene⁷. Each probe contained a fluorescent molecule (FAM for B19V, and HEX for the SARS-CoV-2

105 N gene), as well as ZEN, a proprietary internal quencher from IDT; and IBFQ, Iowa Black FQ.

106

Target		Sequence
Parvovirus B19	Forward	CCACTATGAAAACTGGGCAATA
	Reverse	GCTGCTTTCACTGAGTTCTTCA
	Probe	AATGCAGATGCCCTCCACCCAG
SARS-CoV-2 N gene	Forward	CATTACGTTTGGTGGACCCT
	Reverse	CCTTGCCATGTTGAGTGAGA
	Probe	CGCGATCAAAACAACGTCGG

107

108

109 Concentrations of RNA targets were converted to concentrations per dry weight of solids

110 (copies per gram dry weight (cp/g)) using dimensional analysis. The error is reported as

standard deviations and includes the errors associated with the Poisson distribution and the

variability among the replicates. Three positive droplets across 6 merged wells corresponds to a

concentration ~1000 cp/g for solids, respectively). Measured concentrations in the samples are
 available through the Stanford Digital Repository (https://doi.org/10.25740/zn011jk5743).

115

116 Parvovirus Case and Symptom Surveillance. Case and syndromic data used in this study 117 came from Epic Cosmos, a dataset created in collaboration with a community of Epic health 118 systems (Epic Cosmos, Epic Systems Corporation, Wisconsin) representing more than 284 119 million patients from all 50 states, D.C., Lebanon, and Saudi Arabia. Epic Cosmos reflects US 120 population demographics (ref). First, all encounters in the dataset were geographically and 121 temporally filtered to encounters within Montgomery county, Texas between 16 October 2023 122 and 16 October 16 2024. From this subset, data for parvovirus cases was selected using 123 International Classification of Disease, Tenth Edition (ICD-10) codes B08.3, B34.3 and B97.6 124 (Erythema infectiosum; Parvovirus infection, unspecified; and Parvovirus as the cause of diseases classified elsewhere).^{8,9} The laboratory testing results for parvovirus were not available 125 126 through Epic Cosmos; however, prior epidemiological studies have also relied on ICD codes for 127 diagnosis given many children are diagnosed clinically without confirmatory laboratory 128 confirmation. Data was then aggregated at the weekly level and exported as CSV files for

analysis. Data are redacted for weeks with fewer than or equal to 10 cases. The date assignedto each week is the last day of the week.

131

132 We also used quarterly data, defined as January through March and every 3 months following,

- 133 for parvovirus cases as defined above, and hydrops fetalis. Hydrops fetalis diagnosis drew on
- 134 32 ICD-10 codes encompassing hydrops fetalis due to hemolytic disease, maternal care for
- hydrops fetalis, and encounter for antenatal screening for hydrops fetalis (ICD-10 P56.*; O36.*;
- 136 Z36.81) . The data assigned to each quarter represents the last day of the quarter.
- 137

Statistics. All data series were not normally distributed based on the Wilks Shapiro test of normality (p<0.05 for case data, B19V, and B19V normalized by PMMoV). Concentrations of D10V (and D10V (page aligned by D10A) ((D10V (D10A)))

- B19V and B19V normalized by PMMoV (B19V/PMMoV) were compared between the two
 WWTPs using Kruskal Wallis tests. We compared the detection of B19V DNA at the two plants
- 142 using a chi-square test. We tested the hypothesis that weekly median concentrations of B19V
- and B19V/PMMoV are associated with parvovirus case data using Kendall's tau. Values in the
- 144 case data < 10 were replaced with 10. We also tested for associations using weekly averages
- 145 instead of medians. In total, we carried out 11 statistical tests; to account for multiple
- 146 comparisons, we conservatively used p = 0.005 (0.05/11) as cut off for alpha = 0.05.
- 147

148 Results

QA/QC. The previously designed B19V assay was found to be both specific and sensitive, able
 to detect their intended targets with no cross reactivity. In silico analysis indicated that the assay
 did not cross react with non-target sequences, and that the assay was able to detect all

- 152 parvovirus B19. There was no cross reactivity identified in vitro.
- 153

Negative and positive extraction and PCR controls on all plates used for environmental sample
testing were negative and positive. Median (interquartile range, IQR) BCoV recoveries were 1.1
(0.75, 1.2) for WWTP186 and 0.89 (0.7, 1.1) for WWTP187. Median (IQR) PMMoV were
1.9x10⁸ (1.2x10⁸ - 2.7x10⁸) cp/g for WWTP186 and 2.2x10⁸ (1.4x10⁸ - 3.5x10⁸) cp/g for

- 158 WWTP187 (Figure 2). BCoV recoveries indicate median recoveries close to 100%, and stable
- PMMoV between and within WWTPs, respectively. This suggests B19V DNA concentrations
 can be compared over time and between WWTPs as they have similar high recoveries and
- 161 consistent fecal strength. Median (IQR) ratio of SARS-CoV-2 N gene concentrations in stored
- 162 versus fresh samples was 1.5 (1.2,1.8) at both WWTP suggesting minimal effect of storage.
- 163
- Additional details related to the EMMI guidelines. Across all the samples run in this study (n=220), the average (standard deviation) number of partitions (droplets) for the across the 6 replicate wells was 89,483 (27,001) for the reaction for duplex B19V and SARS-CoV-2 N gene assays. The volume of the partitions, as reported by the machine vendor is 0.00085 μ L. The mean (standard deviation) of copies per partition for each target was 1.04x10⁻⁴ (2.37x10⁻⁴) and 2.57x10⁻³ (3.11x10⁻³) for B19V and SARS-CoV-2 N gene, respectively. An example fluorescent plot from the QX200 (2 color reader), as well as a spreadsheet version of the EMMI checklist is
- 171 included in the Stanford Digital Repository with the deposited data
- 172 (https://doi.org/10.25740/zn011jk5743).



- 184 Figure S1. Map of the two sewersheds from which wastewater solids were processed in this study. This
- 185 figure was generated using Tableau; map layer from OpenStreetMap which is open
- 186 access(openstreetmap.org/copyright).





190 Figure S2. Concentrations of PMMoV measured in the samples, as previously reported⁶. Error

bars represent standard deviations and in some cases are too small to be seen.



192

193 Figure S3. Box and whisker plot of B19V DNA concentrations at the two WWTPs. Lower,

194 middle, and upper lines of boxes represent the 25th, 50th (median), and 75th percentiles.

195 Whiskers extend to minimum and maximum measurements. Data points are shown as circles.

196

197

198

(1) Simpson, A.; Topol, A.; White, B.; Wolfe, M. K.; Wigginton, K.; Boehm, A. B. Effect of
Storage Conditions on SARS-CoV-2 RNA Quantification in Wastewater Solids. *PeerJ* 2021,
9, e11933. https://doi.org/10.7717/peerj.11933.

- (2) Toppinen, M.; Norja, P.; Aaltonen, L.-M.; Wessberg, S.; Hedman, L.; Söderlund-Venermo,
 M.; Hedman, K. A New Quantitative PCR for Human Parvovirus B19 Genotypes. *J. Virol. Methods* 2015, *218*, 40–45. https://doi.org/10.1016/j.jviromet.2015.03.006.
- (3) Boehm, A. B.; Wolfe, M. K.; Wigginton, K. R.; Bidwell, A.; White, B. J.; Hughes, B.; Duong;
 Chan-Herur, V.; Bischel, H. N.; Naughton, C. C. Human Viral Nucleic Acids Concentrations
 in Wastewater Solids from Central and Coastal California USA. *Sci. Data* 2023, *10*, 396.
- (4) Symonds, E. M.; Nguyen, K. H.; Harwood, V. J.; Breitbart, M. Pepper Mild Mottle Virus: A
 Plant Pathogen with a Greater Purpose in (Waste)Water Treatment Development and
 Public Health Management. *Water Res.* 2018, 144, 1–12.
 https://doi.org/10.1016/j.watros.2018.06.066
- 211 https://doi.org/10.1016/j.watres.2018.06.066.
- 212 (5) McClary-Gutierrez, J. S.; Aanderud, Z. T.; Al-faliti, M.; Duvallet, C.; Gonzalez, R.; Guzman, 213 J.; Holm, R. H.; Jahne, M. A.; Kantor, R. S.; Katsivelis, P.; Kuhn, K. G.; Langan, L. M.; 214 Mansfeldt, C.; McLellan, S. L.; Mendoza Grijalva, L. M.; Murnane, K. S.; Naughton, C. C.; 215 Packman, A. I.; Paraskevopoulos, S.; Radniecki, T. S.; Roman, F. A.; Shrestha, A.; Stadler, L. B.; Steele, J. A.; Swalla, B. M.; Vikesland, P.; Wartell, B.; Wilusz, C. J.; Wong, J. C. C.; 216 217 Boehm, A. B.; Halden, R. U.; Bibby, K.; Delgado Vela, J. Standardizing Data Reporting in the Research Community to Enhance the Utility of Open Data for SARS-CoV-2 Wastewater 218 219 Surveillance. Environ. Sci. Water Res. Technol. 2021, 7 (9), 1545–1551. 220 https://doi.org/10.1039/D1EW00235J.
- (6) Boehm, A. B.; Wolfe, M. K.; Bidwell, A. L.; Zulli, A.; Chan-Herur, V.; White, B. J.; Shelden,
 B.; Duong, D. Human Pathogen Nucleic Acids in Wastewater Solids from 191 Wastewater
 Treatment Plants in the United States. *Sci. Data* 2024, *11* (1), 1141.
 https://doi.org/10.1038/s41597-024-03969-8.
- (7) Huisman, J. S.; Scire, J.; Caduff, L.; Fernandez-Cassi, X.; Ganesanandamoorthy, P.; Kull,
 A.; Scheidegger, A.; Stachler, E.; Boehm, A. B.; Hughes, B.; Knudson, A.; Topol, A.;
 Wigginton, K. R.; Wolfe, M. K.; Kohn, T.; Ort, C.; Stadler, T.; Julian, T. R. WastewaterBased Estimation of the Effective Reproductive Number of SARS-CoV-2. *Environ. Health Perspect.* 2022, *130* (5), 057011–1.
- 230 (8) *ICD-10 Version:2019*. https://icd.who.int/browse10/2019/en (accessed 2024-12-12).
- 231 (9) ICD-10: International Statistical Classification of Diseases and Related Health Problems :
- Tenth Revision, 2004, Spanish version, 1st edition published by PAHO as Publicación
 Científica 544.